CINCINNATI (WKRC) - A breakthrough device is providing new hope for brain cancer survivors, as demonstrated by the inspiring journey of Patty Young. Diagnosed with a brain tumor after suffering a ...

Optune Lua is FDA approved for use with immunotherapy or docetaxel in metastatic stage IV NSCLC post-platinum treatment. The device uses tumor treating fields to disrupt cancer cell division, offering ...

Lung cancer can be treated with small molecules formulated as pills as well as biological medications that are injected or infused, both as standalone treatments or as part of drug combinations. A ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of ...

Novocure (NVCR) announced that the FDA approved its new head flexible electrode, or HFE, transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme, or ...

Young medical companies with new therapies often navigate a challenging path. That's true today for NovoCure (NASDAQ: NVCR), which makes a wearable device for treating cancer. The average investor ...

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

Shares of NovoCure recently jumped in response to positive results from an important lung cancer trial. The company markets Optune, a battery-powered hat proven to suppress the growth of brain tumors.

CHICAGO — A medical device made by Novocure that creates electric fields in the lungs via wearable skin patches extended the survival of patients with lung cancer in a clinical trial, researchers ...